Print E-mail

The Cough Company Announces Partnership to Develop Prescription Cough Products

MORRISTOWN, New Jersey – August 9, 2010 – The Cough Company, a life sciences product development company focused on improving therapies for cough, pain, and women’s health today announced the closing of a product development deal with a billion-dollar multinational pharmaceutical company. The contract calls for the development of two prescription cough products using the Company’s proprietary ion exchange resin technology, REA Ion Exchange Resins™. Due to the confidentiality provisions of the partnership agreement, the identity of the partner was not disclosed.

"This development partnership puts The Cough Company well on the road to being a fully functional product development company," said Dr. William Howard, President and CEO of The Cough Company. "We believe the products developed through this partnership will ultimately generate significant royalty payments. Both products contain drug formulations based on our REA Ion Exchange Resins™."

"The great thing about our new partnership is that we were able to get The Cough Company started without any outside investors. That significantly alters the definition of success should we ever get to the point of selling the company, which is our goal," Dr. Howard continued. "We will continue to expand our patent portfolio, find a partner for our OTC products, and begin to develop some products which we will market ourselves."

Cough is the most common reason for a patient to visit a doctor, according to CDC statistics, yet there have been no new NDA prescription cough products introduced in over 20 years. The total market for cough products equals 30 million prescriptions annually.

About The Cough Company, Inc.:
The Cough Company is a specialty pharmaceutical company focused on the development of new and improved respiratory, pain, and women’s health products. The Company is currently focused on prescription and OTC cough medications, with pain and women’s health products in the pipeline. The Company’s 505(b)(2) strategy means that products can be developed quickly and with low regulatory hurdles which reduces the overall time to market and leads to lower total development cost for a patent-protected, NDA-approved drug product.

###

Source: Alitair Pharmaceuticals, Inc.
www.alitair.com

Contact: Faith Pomeroy-Ward
Vice President, Corporate Development
817-490-5152 | This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 
Solution Managers